Skip to content

Daclatasvir

Daklinza (daclatasvir) is a small molecule pharmaceutical. Daclatasvir was first approved as Daklinza on 2015-07-24. It is used to treat chronic hepatitis c and hepatitis c in the USA. Daklinza's patents are valid until 2031-06-13 (FDA).
Trade Name Daklinza
Common Name Daclatasvir
Indication chronic hepatitis c, hepatitis c
Drug Class Antivirals: NS5A inhibitors
Daclatasvir
Get full access now